With our NBD C6-Cer incorporation-based methodology, we successfully assessed alterations of GCS activity in cultured cancer cells and in cell suspensions prepared from tumors and other tissues (bone marrow, brain, kidney, small intestine, whole blood cells). This evidence concerns the gene UGCG and cancer.